Tokyo, Japan, September 28, 2015 --- Teijin Pharma Limited, the core company of the Teijin Group’s medical and pharmaceutical business, announced today that it has agreed with PeptiDream Inc., a Tokyo-based biopharmaceutical company, to jointly research and develop macrocyclic and constrained peptides.
PeptiDream researches macrocyclic and constrained peptides with its proprietary Peptide Discovery Platform System (PDPS). These cyclically shaped peptides which include non-natural amino acids, are expected to have advantages of both low- and high-molecular-weight pharmaceuticals, and affect various drug targets. They are expected to lead to many more drug discoveries, which have been in decline.
Teijin Pharma will combine its technologies and experience with PeptiDream’s PDPS technology to discover innovative pharmaceuticals based on various drug targets. Teijin Pharma will also research new low-molecular-weight pharmaceuticals by using data on macrocyclic and constrained peptides.
Strengthening relationships with external partners is one of Teijin’s key strategies for transformation and growth, which has led the company to expand its collaborations with medical and pharmaceutical enterprises that offer original technologies.
Current drug discovery research is focused on the discovery of low- and high-weight molecular pharmaceuticals, such as antibody preparations. Progress in drug discoveries has depleted the number of new targets, leading to the problem of declining efficiency in discovery research.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the areas of sustainable transportation, information and electronics, safety and protection, environment and energy, and healthcare. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has some 150 companies and around 16,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY786.2 billion (USD 6.6 billion) and total assets of JPY 823.7 billion (USD 6.9 billion) in the fiscal year ending March 31, 2015.
+81 3 3506 4055
Information in the press releases is current on the date of the announcement.
It is subject to change without prior notice.